Skip to main content

Table 1 Patient characteristics

From: Effects of Tocilizumab in COVID-19 patients: a cohort study

 

All (N = 60)

Died (n = 9)

Age, median (range), years

54 (26–87)

58 (33–84)

Male, n (%)

40 (66.7)

8 (88.9)

Ethnicity

 Hispanic

38 (63.3)

6 (66.7)

 Black

14 (23.3)

2 (22.2)

 White

7 (11.7)

1 (11.1)

 Asian

1 (1.7)

0 (0.0)

Comorbidities

 Obese (BMI > 30)

35 (58.3)

6 (66.7)

 Hypertension

32 (53.3)

8 (88.9)

 Diabetes

15 (25.0)

3 (33.3)

 Congestive heart failure

4 (6.7)

1 (11.1)

 Coronary artery disease

1 (1.7)

0 (0.0)

 Asthma

4 (6.7)

0 (0.0)

 COPD

1 (1.7)

1 (11.1)

 Obstructive sleep apnea

2 (3.3)

0 (0.0)

 HIV

1 (1.7)

0 (0.0)

 Transplant

1 (1.7)

0 (0.0)

Concomitant therapies

 Hydroxychloroquine

52 (86.7)

8 (88.9)

 Corticosteroids

32 (53.3)

5 (55.6)

 Inhaled nitric oxide

5 (8.3)

1 (11.1)

 Intravenous immunoglobulin (IVIG)

4 (6.6)

0 (0.0)

 Tacrolimus

2 (3.3)

1 (11.1)

 Convalescent plasma

2 (3.3)

0 (0.0)

 Plasmapheresis

1 (1.7)

0 (0.0)

Time from symptom onset to hospital admission, median (range), days

6 (1–14)

7 (1–14)

Time from hospital admission to receiving tocilizumab, median (range), days

2 (0–12)

1 (0–4)

Time from symptom onset to receiving tocilizumab, median (range), days

8 (1–21)

8 (1–15)

  1. Note: abnormal medians highlighted in bold
  2. aLuo H, et al. Clin Lab 2019;65(3).